Will the recent publication of the MA.20 and EORTC 22922 studies in NEJM, showing no survival advantage from regional nodal irradiation in early-stage breast cancer patient following surgery, change your standard of care for these patients?
How much will you weigh the demonstrated disease-free survival, including distant disease-free survival, in your recommendations?
Thank you for the excellent summary! Will you c...
I have not made the jump to node negative but woul...
Thank you very much. Will this modify the use of C...
Since current practice is to get SN only, how do t...
The benefit in terms of disease-free survival on M...
Thank you for the excellent summary. "In the c...
Any thoughts regarding the role of Oncotype and it...